Related Experiment Video

Updated: Aug 7, 2025

Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury
07:07

Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury

Published on: February 10, 2020

10.6K

Anticholinergics: A potential option for preventing posttraumatic epilepsy

Viviam Sanabria1, Simone Romariz1, Matheus Braga1

  • 1Department of Physiology, Universidade Federal de São Paulo, São Paulo, Brazil.

Frontiers in Neuroscience
|March 13, 2023
PubMed

Insights

Anticholinergic drugs show promise in preventing epilepsy after traumatic brain injury (TBI). Early treatment may reduce seizure frequency and severity, potentially lowering the risk of developing posttraumatic epilepsy (PTE).

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epileptology

Background:

  • Traumatic brain injury (TBI) can lead to the development of epilepsy.
  • The cholinergic system plays a role in the epileptogenic process.
  • Anticholinergic drugs have demonstrated potential in preclinical models for epilepsy prevention.

Purpose of the Study:

  • To review the role of the cholinergic system in epilepsy.
  • To summarize findings on anticholinergic drugs for preventing posttraumatic epilepsy (PTE).
  • To discuss the rationale for using anticholinergics specifically for PTE prevention.

Main Methods:

  • Review of basic science studies on anticholinergics and epilepsy.
  • Analysis of animal models investigating anticholinergic efficacy in PTE.
  • Examination of new clinical trial protocols for anticholinergic treatment post-TBI.

Main Results:

  • Anticholinergic treatment in the acute phase after brain injury reduces seizure frequency and severity.
  • Anticholinergic therapy decreases the number of spontaneous recurrent seizures (SRS) in models.
  • Evidence suggests anticholinergics may lower the risk of developing PTE.

Conclusions:

  • Anticholinergic drugs represent a potential therapeutic strategy for PTE prevention.
  • Targeting the cholinergic system acutely after TBI may modify epileptogenesis.
  • Anticholinergic treatment may be particularly effective for preventing PTE compared to other epilepsy types.
Keywords:
anticholinergicsepileptogenesispharmacological treatmentpreventiontraumatic brain injury

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.1K
Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury09:16

Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury

Published on: June 21, 2019

25.7K

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
742
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
456
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
489
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
802
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
235
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
233